Revealed: global funds, from BlackRock to Temasek, back China’s largest biotech firms

South China Morning PostEN 1 min read 100% complete by Julie ZhangJanuary 23, 2026 at 01:30 AM

AI Summary

short article 1 min

Global funds, including BlackRock and Temasek, are investing heavily in China's largest biotech firms. These international institutional investors have been building significant stakes in Chinese biotech companies listed on the Hong Kong stock exchange over the past decade. BlackRock, for example, holds substantial shares in Innovent Biologics, 3SBio, WuXi AppTec, and WuXi Biologics, in some cases exceeding the 5% disclosure threshold. This investment reflects the growing importance of Chinese biotech and pharmaceutical companies on the global stage, with foreign investors seeking to capitalize on their future success. The investments provide capital for Chinese firms to grow and compete internationally.

Key Entities & Roles

Key Player Opposition Context

Hang Seng Biotech Index 40% Japan 50% 3SBio 50% WuXi AppTec 50% WuXi Biologics 50% Takeda 60% Innovent Biologics 70% Hong Kong ×270% China 80% BlackRock ×490%

Keywords

biotech firms 100% pharmaceutical firms 80% foreign investors 70% blackrock 60% institutional investors 60% china 50% global funds 50% shareholdings 50% hong kong 40% stake 40%

Sentiment Analysis

Neutral

Score: 0.10

Source Transparency

Source

South China Morning Post

Classification Confidence

90%

Geographic Perspective

China

This article was automatically classified using rule-based analysis.

Topic Connections

Explore how the topics in this article connect to other news stories

No topic relationship data available yet. This graph will appear once topic relationships have been computed.

biotech firms pharmaceutical firms foreign investors blackrock institutional investors china global funds shareholdings hong kong stake

Explore Full Topic Graph

Find Similar Articles

AI-Powered

Discover articles with similar content using semantic similarity analysis.